We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
-7.72%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$157M
AUM Growth
+$31.7M
Cap. Flow
+$45.5M
Cap. Flow %
28.95%
Top 10 Hldgs %
45.06%
Holding
108
New
39
Increased
16
Reduced
23
Closed
22

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$8.9M
2
MA icon
Mastercard
MA
+$8.7M
3
FISV
Fiserv Inc
FISV
+$8.43M
4
PYPL icon
PayPal
PYPL
+$6.75M
5
FIS icon
Fidelity National Information Services
FIS
+$4.01M

Top Sells

Rank Stock Value
1
XLNX
Xilinx Inc
XLNX
+$5.13M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$4.35M
3
NUAN
Nuance Communications, Inc.
NUAN
+$3.59M
4
CONE
CyrusOne Inc Common Stock
CONE
+$3.47M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 44.39%
2 Technology 25.46%
3 Financials 19.54%
4 Consumer Discretionary 2.88%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
51
BridgeBio Pharma
BBIO
$16.4B
$866K 0.55%
85,300
+51,450
+152% +$528K
XENE icon
52
Xenon Pharmaceuticals
XENE
$6.11B
$856K 0.54%
27,992
-34,914
-56% -$1.05M
CCCC icon
53
C4 Therapeutics
CCCC
$428M
$843K 0.54%
34,760
+3,267
+10% +$79.3K
TVTX icon
54
Travere Therapeutics
TVTX
$5.68B
$838K 0.53%
32,501
-21,602
-40% -$574K
ACAD icon
55
Acadia Pharmaceuticals
ACAD
$5.07B
$826K 0.53%
+34,116
New +$826K
LKFT
56
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.88B
$819K 0.52%
+13,209
New +$808K
BCYC
57
Bicycle Therapeutics
BCYC
$288M
$803K 0.51%
+18,298
New +$854K
MRUS
58
DELISTED
Merus
MRUS
$803K 0.51%
30,388
-23,452
-44% -$628K
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$802K 0.51%
9,753
+517
+6% +$52.9K
RCKT icon
60
Rocket Pharmaceuticals
RCKT
$382M
$764K 0.49%
48,191
+1,278
+3% +$22.1K
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
$734K 0.47%
22,812
-11,675
-34% -$424K
NGM
62
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$705K 0.45%
+46,243
New +$721K
CBAY
63
DELISTED
Cymabay Therapeutics
CBAY
$645K 0.41%
+207,307
New +$653K
BEAM icon
64
Beam Therapeutics
BEAM
$2.77B
$636K 0.4%
11,102
-2,436
-18% -$160K
GOSS icon
65
Gossamer Bio
GOSS
$88.9M
$608K 0.39%
+70,042
New +$675K
NVTA
66
DELISTED
Invitae Corporation
NVTA
$602K 0.38%
75,472
+30,505
+68% +$307K
EWTX icon
67
Edgewise Therapeutics
EWTX
$4.81B
$579K 0.37%
+59,733
New +$769K
RLMD icon
68
Relmada Therapeutics
RLMD
$477M
$577K 0.37%
+21,381
New +$442K
TPTX
69
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$565K 0.36%
+21,037
New +$707K
IDYA icon
70
IDEAYA Biosciences
IDYA
$3.55B
$554K 0.35%
49,527
+8,908
+22% +$131K
NTRA icon
71
Natera
NTRA
$45.1B
$547K 0.35%
13,448
+2,409
+22% +$145K
BMEA icon
72
Biomea Fusion
BMEA
$93.5M
$504K 0.32%
+112,918
New +$732K
UTHR icon
73
United Therapeutics
UTHR
$22.1B
$477K 0.3%
2,657
-3,609
-58% -$688K
PRTA icon
74
Prothena Corp
PRTA
$473M
$474K 0.3%
12,953
-15,125
-54% -$545K
BLU
75
DELISTED
BELLUS Health Inc.
BLU
$448K 0.28%
+65,174
New +$420K
1 2
3
4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2022 Portfolio in Review

As of Q1 2022, HighVista Strategies held 108 positions worth $157M, up 25% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

HighVista Strategies deployed $45.5M of net new capital in Q1 2022, opening 39 new positions and adding to 16 existing holdings. Its largest new stake was Visa: 41,135 shares worth $9.12M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $1.05M trimmed.

  • HighVista Strategies's largest Q1 2022 buy was Visa: 41,135 shares worth $9.12M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q1 2022, an estimated $1.72M increase.
  • HighVista Strategies's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $1.05M.
  • HighVista Strategies fully exited Xilinx Inc in Q1 2022, selling an estimated $5.13M.
  • HighVista Strategies's ten largest holdings make up 45% of its $157M portfolio in Q1 2022.
  • HighVista Strategies opened 39 new positions and closed 22 in Q1 2022.
  • HighVista Strategies's portfolio value rose 25% quarter-over-quarter to $157M.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.